clinical practice
“The students in this study agreed they
had a role in pressure injury prevention and
that it should be a priority. The greatest
concern about pressure injury prevention
attitudes is personal competency beliefs,”
the study said.
It added that the findings highlight
the need for a comprehensive approach
to increase students’ knowledge in this
area and for students to have adequate
experiences in clinical units with a high
focus on pressure injury prevention.
The authors also called on educators,
registered nurses and nurse supervisors to
involve students in pressure injury prevention.
Nursing Review spoke with lead author
Professor Kim Usher, head of the School of
Health at UNE, to discuss the ways nurses
can help students improve their approach
to pressure injuries and what changes are
needed in training organisations. give the best quality of care to patients.
And pressure injuries are something
that cause a lot of concern and distress
to the patient. They can also lead to a
number of complications and can extend
hospitalisation, so they add a lot of costs to
our healthcare system. In some countries,
the costs have become so great that
they’ve started to penalise hospitals that
report high numbers of pressure injuries.
NR: What are your concerns about the
lack of pressure injury knowledge? Well, importantly, students did show that
they had some knowledge areas covered:
nutrition, risk assessment, and the aetiology
and development of pressure injuries.
KU: Pressure injuries are an indicator of
quality care, so we should be aiming to
What were some of the important
aspects of pressure injury prevention that
students weren’t fully across?
For me, the biggest concern is that a lot of
students in this study lacked knowledge
about prevention. They also lacked the
ability to accurately assess the levels of
pressure injuries.
On the flip side, in which areas did you
see high scores?
Also, students scored quite high on
attitudes, which is similar to findings in
other countries. That means Australian
nursing students have a good attitude
towards pressure injury prevention. They
see it as part of their role.
Unfortunately, students scored low
on confidence. They tended not to feel
confident that they were able to reduce
pressure injuries or that they knew the
strategies to do so.
How can pressure injury training
be improved?
Nursing curricula across Australia need
to have more of a focus on pressure
injuries, on strategies to assess and prevent
them. Also, I’d like to see that when our
students go on clinical – as we found
students who’d been in more varied
areas of clinical had better knowledge of
pressure injury prevention strategies – I’d
like to see it mandated that students have
to experience a number of different areas
of clinical during their undergraduate
nursing program. ■
at www.seqirus.com.au/PIs
given at the same time as other vaccines although no clinical data on concomitant administration with other vaccines are available. Immunisation should be carried out on separate limbs. It should be noted that any adverse
reactions might be intensified. VERY COMMON AND COMMON ADVERSE EVENTS: Local reactions, including redness, swelling, induration, pain at the injection site and ecchymosis. Systemic reactions including fever,
malaise, shivering, fatigue, headache, sweating, myalgia, arthralgia. These reactions usually disappear within 1-2 days without treatment. DOSAGE AND USAGE: A single 0.5mL dose should be administered by intramuscular
injection into the deltoid muscle. Bring FLUAD ® to room temperature prior to injection. Gently shake before use. After shaking, the normal appearance of FLUAD ® is a milky-white suspension.
Based on Approved Product Information 16 November 2017. NIP = National Immunisation Programme. REFERENCES: 1. FLUAD Approved Product Information, November 2017. 2. Media
Release: Prime Minister, Minister for Health, 18th February 2018. Available at: https://www.pm.gov.au/media/ground-breaking-flu-vaccines-protect-millions-aussies Accessed 21 March
2018. 3. Seqirus Data on File. Seqirus (Australia) Pty Ltd. ABN 66 120 398 067, 63 Poplar Road Parkville, Victoria 3052. www.seqirus.com.au. Medical Information: 1800 642 865.
FLUAD ® is a registered trademark and Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. Date of preparation: March 2018. SEQ/FTIV/0318/0006. 14720.
• FLUAD is tailored to help protect those
aged 65 years and over against influenza
• Over 90 million doses distributed and
registered in over 30 countries worldwide
®
1
3
influenza vaccine, adjuvanted
influenza vaccine, adjuvanted
NO W AVA IL A B L E O N NIP
2
1
27/3/18 2:32 pm
nursingreview.com.au
| 19